European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
-
Randomized Controlled Trial
Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin.
In the absence of a licensed formulation in many countries worldwide, ADV6209, an innovative 2mg/ml oral solution of midazolam containing cyclodextrin, has been developed for moderate sedation in paediatric patients. Population pharmacokinetics for ADV6209 is reported. ⋯ Pharmacokinetic parameters were close to those reported in the literature with midazolam extemporaneous oral solutions or syrups, demonstrating that cyclodextrin had no significant effect on measured parameters.